184.71 USD
+0.9 (+0.49%)
184.71 USD
0 (0%)
Taking everything into account, BGNE scores 3 out of 10 in our fundamental rating. BGNE was compared to 525 industry peers in the Biotechnology industry. BGNE may be in some trouble as it scores bad on both profitability and health. BGNE is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
- In the past year BGNE has reported negative net income.
- BGNE had a negative operating cash flow in the past year.
- BGNE had negative earnings in each of the past 5 years.
- BGNE had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- BGNE's Return On Assets of -15.97% is amongst the best of the industry. BGNE outperforms 81.63% of its industry peers.
- The Return On Equity of BGNE (-26.99%) is better than 80.74% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.97% | ||
| ROE | -26.99% | ||
| ROIC | N/A |
ROA(3y)-21.61%
ROA(5y)-31.52%
ROE(3y)-32.05%
ROE(5y)-48.63%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- BGNE has a better Gross Margin (83.13%) than 87.63% of its industry peers.
- BGNE's Gross Margin has been stable in the last couple of years.
- BGNE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 83.13% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.09%
GM growth 5Y-0.25%
2. Health
2.1 Basic Checks
- BGNE does not have a ROIC to compare to the WACC, probably because it is not profitable.
- BGNE has more shares outstanding than it did 1 year ago.
- BGNE has a worse debt/assets ratio than last year.
2.2 Solvency
- BGNE has an Altman-Z score of 3.53. This indicates that BGNE is financially healthy and has little risk of bankruptcy at the moment.
- The Altman-Z score of BGNE (3.53) is better than 77.03% of its industry peers.
- A Debt/Equity ratio of 0.31 indicates that BGNE is not too dependend on debt financing.
- Looking at the Debt to Equity ratio, with a value of 0.31, BGNE is doing worse than 71.02% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.31 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.53 |
ROIC/WACCN/A
WACC10.79%
2.3 Liquidity
- BGNE has a Current Ratio of 1.94. This is a normal value and indicates that BGNE is financially healthy and should not expect problems in meeting its short term obligations.
- BGNE has a worse Current ratio (1.94) than 76.68% of its industry peers.
- BGNE has a Quick Ratio of 1.72. This is a normal value and indicates that BGNE is financially healthy and should not expect problems in meeting its short term obligations.
- With a Quick ratio value of 1.72, BGNE is not doing good in the industry: 79.15% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.94 | ||
| Quick Ratio | 1.72 |
3. Growth
3.1 Past
- BGNE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -457.37%.
- Looking at the last year, BGNE shows a very strong growth in Revenue. The Revenue has grown by 52.08%.
- BGNE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 67.79% yearly.
EPS 1Y (TTM)-457.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-159.34%
Revenue 1Y (TTM)52.08%
Revenue growth 3Y101.8%
Revenue growth 5Y67.79%
Sales Q2Q%26.79%
3.2 Future
- Based on estimates for the next years, BGNE will show a very strong growth in Earnings Per Share. The EPS will grow by 77.27% on average per year.
- The Revenue is expected to grow by 25.88% on average over the next years. This is a very strong growth
EPS Next Y35.87%
EPS Next 2Y36.2%
EPS Next 3Y34.59%
EPS Next 5Y77.27%
Revenue Next Year52.03%
Revenue Next 2Y37.72%
Revenue Next 3Y30.68%
Revenue Next 5Y25.88%
3.3 Evolution
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- BGNE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year BGNE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- BGNE's earnings are expected to grow with 34.59% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.2%
EPS Next 3Y34.59%
5. Dividend
5.1 Amount
- BGNE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BEIGENE LTD-ADR / BGNE FAQ
What is the fundamental rating for BGNE stock?
ChartMill assigns a fundamental rating of 3 / 10 to BGNE.
Can you provide the valuation status for BEIGENE LTD-ADR?
ChartMill assigns a valuation rating of 1 / 10 to BEIGENE LTD-ADR (BGNE). This can be considered as Overvalued.
Can you provide the profitability details for BEIGENE LTD-ADR?
BEIGENE LTD-ADR (BGNE) has a profitability rating of 3 / 10.
Can you provide the expected EPS growth for BGNE stock?
The Earnings per Share (EPS) of BEIGENE LTD-ADR (BGNE) is expected to grow by 35.87% in the next year.
How sustainable is the dividend of BEIGENE LTD-ADR (BGNE) stock?
The dividend rating of BEIGENE LTD-ADR (BGNE) is 0 / 10 and the dividend payout ratio is -2.03%.